A Phase 4 interventional study of Nintedanib and Placebo in Myositis Associated Interstitial Lund Disease (MA-ILD), sponsored by Rohit Aggarwal, MD. Completed at 10 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Rohit Aggarwal, MD · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies testing nintedanib in Lung Diseases, Interstitial — 1 open to participants now, 1 under way, 1 of them phase 3. nintedanib · Lung Diseases, Interstitial.
Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, this one is the 7th largest by enrollment, is the only one that started in 2023, is one of 2 in phase 4, and was the 10th registered.
682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.
Browse Lung Diseases, Interstitial studies →1 of the 11 studies testing nintedanib in Lung Diseases, Interstitial is open now, in 1 country. Recruiting first, the newest first:
National Institute of Geriatrics, Rheumatology and Rehabilitation, Poland · Sites in Poland
Ages 18–74
By country, each count listing its studies:
nintedanib: first FDA approval 2014 (OFEV), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →
Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2023.
This study's enrollment of 62 is close to the median of 60 across 386 interventional studies indexed under Lung Diseases, Interstitial.
Median enrollment 81 across the 11 interventional studies. Of the 9 that completed or were terminated, 8 (89%) have results posted.
This tab as a report to print or save as PDF → With an account.
6 of 11 have an industry lead sponsor. The 6 most frequent:
Rohit Aggarwal, MD is the lead sponsor of 3 studies on the registry; none are open to participants now.
Rohit Aggarwal, MD has 2 studies filed under Lung Diseases, Interstitial — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 11 studies testing nintedanib in Lung Diseases, Interstitial, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This research study will evaluate safety and how well the study drug, nintedanib improve symptoms in participants with myositis associated interstitial lung disease (MA-ILD). Interstitial lung disease is a disorder caused by the abnormal accumulation of cells structures between air sacs of the lungs resulting in thickening, stiffness and scarring of the tissues of the lung.
This study will enroll a total of 134 participants across 15 clinical sites located in the United States. A subset of participants will be enrolled remotely via telemedicine utilizing certified mobile home research nurses and various remote monitoring devices.
The research visits may include a physical exam, vital signs (such as blood pressure, heart rate, etc.), pulmonary function tests (PFT and/or home spirometry), Computerized Tomography (or CT) scans of the chest, blood draws, wearing a physical activity monitor and completing questionnaires. Some of these events may be done at home, at a local facility or remotely (via telemedicine).
Participants enrolled in the study will receive either study drug or placebo for 12 weeks plus the participant's normal standard of care medication for the participant's disease. Placebo is an inactive substance that contains no medicine. Following the initial treatment phase, participants will receive the active study drug (nintedanib) for an additional 12-week period.
Nintedanib is a drug that is currently used and has been approved by the Food and Drug Administration (FDA) for the treatment of idiopathic pulmonary fibrosis (IPF), and has been shown to slow the rate of decline in pulmonary function among patients with IPF as well as interstitial lung disease (ILD) associated with systemic sclerosis or scleroderma. In addition, in March 2020, the FDA approved nintedanib oral capsules to treat patients with chronic fibrosing (scarring) interstitial lung diseases (ILD) with a progressive phenotype (trait).
The original trial registration listed an outcome measure for change in non-primary L-PF scores from Week 12 to Week 24. This did not appear in the final SAP and was removed from the outcome measures list. Additionally, the outcome measure of "L-PF Total Score" was included in the approved SAP, however we were informed a Total Score was not to be generated from the Symptoms and Impacts module scores. L-PF Total Score was included in the SAP in error and was not analyzed.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Clinical diagnosis of myositis or presence of one of the following myositis-specific or -associated autoantibodies).
Fibrosing Interstitial Lung Disease (ILD):
Progressive ILD: Defined as meeting ≥1 of the following criteria within 24 months of the screening visit.
Standard of care (SOC) therapy: (See: SOC and washout under section 6.2 for details)
Allowable IS and GC:
Glucocorticoid (maximum dose ≤20 mg/day; prednisone equivalent). Mycophenolate mofetil (max dose 3 gm/day) Mycophenolic acid (max dose 2,160 mg/day) Azathioprine (max dose 2.5 mg/kg/day) Methotrexate (max dose 25 mg/week Tacrolimus (max dose 10 mg/day) Cyclosporine (max dose 200 mg/day) Leflunomide (max dose 20 mg/day) Sulfasalazine (max dose 3 gm/day) JAK inhibitors (tofacitinib max does 11 mg/day, upadacitinib max dose 15 mg/day, baricitinib max does 4 mg/day) IVIG (Intravenous immunoglobulin) or SQIG (subcutaneous immunoglobulin) (max dose 2 gm/kg/month) is allowed and not considered as SOC IS therapy Rituximab (maximum dose 1000 mg x 2 (2 weeks apart) or 375mg/m2 weekly dose x 4, repeated every > 4 months) Hydroxychloroquine is allowed and not considered as SOC IS therapy. Orencia (max dose of 125 mg SQ once a week or 1 gm monthly IV infusion)
Should remain stable throughout the study.
Exclusion Criteria:
Women of * not willing or able to use at least two highly effective methods of .
Highly effective contraception examples are:
Condoms
A woman is considered of childbearing potential, i.e. fertile, following menarche, and until becoming unless permanently sterile. Permanent sterilization methods include hysterectomy, bilateral salpingectomy, tubal occlusion, and bilateral oophorectomy.
Severe lung disease is defined by the following within the last 6 months before the screening:
Moderate to severe active muscle disease from myositis as per any one of the criteria:
Significant Pulmonary Hypertension (PH) is defined by any of the following:
Increased bleeding risk, defined by any of the following:
Patients who require
Any of the following within 3 months of screening:
Severe Cardiovascular disease, any of the following:
Current or recent use of one or more of the following medications (See: SOC and washout under section 6.2 for details)
Safety laboratory abnormality as any one of below
White blood cells \< 3000/mm3
-
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Reproductive potential
Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.
Criteria about it usually ask for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Immunosuppression
A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.
Read whether the line is about a condition or about medicines, and which medicines and doses it means.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
TIA (transient ischaemic attack)
A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.
Stroke symptoms need emergency care at once, even if they go away.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Child-Pugh class
A score of how well the liver works in people with liver disease such as cirrhosis: class A is mild, B moderate and C severe.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Placebo twice a day (BID) plus standard of care (SOC) Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
Drug: Nintedanib · Drug: Placebo · Drug: Standard of Care
Nintedanib 150 mg BID + SOC Immunosuppressive Therapy for 12 weeks followed by open-label Nintedanib 150mg BID + SOC Immunosuppressive Therapy for additional 12 weeks.
Drug: Nintedanib · Drug: Standard of Care
Nintedanib 150 mg BID
Also known as: OFEV
Placebo comparator
Patients may receive up to 2 standard-of-care immunosuppressants (IS): either 1 glucocorticoid (GC) + 1 non-GC IS, or 2 non-GC IS if not on GC. IS must be used ≥12 weeks (≥4 weeks for GC) with stable doses ≥4 weeks (≥2 weeks for GC) before screening. Allowed therapies and max doses: GC ≤20 mg/day, mycophenolate mofetil 3 g/day, mycophenolic acid 2160 mg/day, azathioprine 2.5 mg/kg/day, methotrexate 25 mg/week, tacrolimus 10 mg/day, cyclosporine 200 mg/day, leflunomide 20 mg/day, sulfasalazine 3 g/day, JAK inhibitors (tofacitinib 11 mg/day, upadacitinib 15 mg/day, baricitinib 4 mg/day), rituximab (1000 mg ×2 or 375 mg/m² weekly ×4 every \>4 months), Orencia 125 mg SQ weekly or 1 g IV monthly. IVIG/SQIG and hydroxychloroquine are allowed but not considered SOC IS therapy. Inhaled lung medications allowed if started \>4 weeks before screening and remain stable.
Change in Living With Pulmonary Fibrosis Symptoms and Impact Questionnaire (L-PF) Dyspnea Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 12
Change in Living With Pulmonary Fibrosis Dyspnea Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 24
Change in Living With Pulmonary Fibrosis Dyspnea Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Week 12 to week 24
Change in Living With Pulmonary Fibrosis Cough Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Cough domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 12
Change in Living With Pulmonary Fibrosis Cough Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Cough domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 24
Change in Living With Pulmonary Fibrosis Energy Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Energy domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 12
Change in Living With Pulmonary Fibrosis Energy Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Energy domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 24
Change in Living With Pulmonary Fibrosis Symptoms Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Symptoms module score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 12
Change in Living With Pulmonary Fibrosis Symptoms Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Symptoms module score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 24
Change in Living With Pulmonary Fibrosis Impacts Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Impacts module score. Scoring is performed as a summary score. Summary score range from 0-1, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 12
Change in Living With Pulmonary Fibrosis Impacts Score
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Impacts module score. Scoring is performed as a summary score. Summary score range from 0-1, the higher the score the greater the impairment.
Time frame: Baseline (week 0) to week 24
Change in Immunosuppressive (IS) Regimen
Percentage of patients requiring an increased dose or a change in their glucocorticoid (GC) / immunosuppression (IS) agent for clinical worsening/flare of MA-ILD
Time frame: Baseline (Week 0) to week 12
Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks
FVC (ml) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 12
Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks
FVC (ml) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 12
Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 24
Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 24
Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 12
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 12
Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 12
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 12
Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 24
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 24
Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 24
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 24
Percentage of Patients With a Relative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
Time frame: Week 12
Percentage of Patients With a Relative Decline From Baseline in FVC (mL) of ≥10%, ≥7.5%, and ≥ 5%
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
Time frame: Week 24
Percentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
Time frame: Week 12
Percentage of Patients With a Relative Decline From Baseline in FVC (%) of ≥10%, ≥7.5%, and ≥ 5%
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
Time frame: Week 24
Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) From Baseline to Week 12
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
Time frame: Week 12
Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (mL) From Baseline to Week 24
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
Time frame: Week 24
Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) From Baseline to Week 12
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
Time frame: Week 12
Percentage of Patients With Stable (+/- < 5%) or Improved FVC (≥ 5, ≥ 7.5, ≥ 10%) (%) From Baseline to Week 24
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
Time frame: Week 24
Time to FVC (mL) Improvement and Decline From Baseline by (≥5%, 7.5%, 10%)
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Time to designated change is calculated based on change from baseline to a follow up visit and time since baseline.
Time frame: Baseline (week 0) to 24 weeks
Time to FVC (%) Improvement and Decline From Baseline by (≥5%, 7.5%, 10%)
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Time to designated change is calculated based on change from baseline to a follow up visit and time since baseline.
Time frame: Baseline (week 0) to 24 weeks
Time to Progression
Defined as either time for event a, b or c. Event a. ≥ 10% decline in FVC (mL) or death or transplant. Event b. ILD worsening definition (per protocol) or death or transplant. Event c. non-elective hospitalization for ILD worsening/flare or death or lung transplant.
Time frame: Baseline (week 0) to week 24
Validity of Forced Vital Capacity (FVC) in ml Measured by Home Spirometry
Validity of FVC (mL) by home spirometry is measured as intraclass correlation coefficient with FVC (mL) obtained by gold standard clinic spirometry. Unsupervised home spirometry values taken +/- 7 days from the in-clinic spirometry dates were averaged to calculate observational values.
Time frame: Baseline (week 0) to week 24
Reliability of Forced Vital Capacity (FVC) in mL by Home Spirometry
Reliability of FVC (mL) by home spirometry is measured as spearman correlation with FVC (mL) of test (baseline) and re-test (Week 12). Unsupervised home spirometry values taken +/- 7 days from the test and re-test dates were averaged to calculate observational values.
Time frame: Baseline (week 0) to week 12
Absolute Change in DLCO(%) From Baseline to 12 Weeks
DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 12
Relative Change in DLCO(%) From Baseline to 12 Weeks
DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 12
Absolute Change in DLCO(%) From Baseline to 24 Weeks
DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 24
Relative Change in DLCO(%) From Baseline to 24 Weeks
DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 24
Absolute Change in FEV1(mL) From Baseline to 12 Weeks
FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 12
Relative Change in FEV1(mL) From Baseline to 12 Weeks
FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 12
Absolute Change in FEV1(mL) From Baseline to 24 Weeks
FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 24
Relative Change in FEV1(mL) From Baseline to 24 Weeks
FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 24
Absolute Change in FEV1(%) From Baseline to 12 Weeks
FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 12
Relative Change in FEV1(%) From Baseline to 12 Weeks
FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 12
Absolute Change in FEV1(%) From Baseline to 24 Weeks
FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.
Time frame: Baseline (week 0) to week 24
Relative Change in FEV1(%) From Baseline to 24 Weeks
FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
Time frame: Baseline (week 0) to week 24
Progression Free Survival
Connective Tissue Disease (CTD)-ILD outcome as per Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT), which is defined as the occurrence of any of the following: death, lung transplant, FVC ≥10% decline, or FVC ≥5% decline with DLCO ≥15% decline. Clinical worsening is defined as death, lung transplant, new/worsening O2 requirement at rest (\>2L), non-elective hospitalization for ILD clinical worsening/flare, ILD worsening definition (per protocol), or out of protocol rescue medication for ILD clinical worsening/flare.
Time frame: Weeks 12 and 24
Steroid Use (Calculated Using Prednisone Dose Equivalents)
Change of steroid dosage (mg/day) from baseline to follow up.
Time frame: Weeks 12 and 24
Change in Supplemental Oxygen Needs From Baseline to Week 12
Change in supplemental oxygen requirement (L) from baseline to follow up.
Time frame: Baseline (week 0) to 12 weeks
Change in Supplemental Oxygen Needs From Baseline to Week 24
Change in supplemental oxygen requirement (L) from baseline to follow up.
Time frame: Baseline (week 0) to 24 weeks
Patient Assessment of Change
Patient Assessment of Change (also known as Patient Global Impression of Change): Overall Assessment of Change by Patient. Patient overall assessment of change in disease status from baseline, reported as 7-point ordinal scale: no change, minimal, moderate, and major worsening as well as minimal, moderate and major improvement.
Time frame: Weeks 12 and 24
Physician Assessment of Change
Physician's overall assessment of change in disease status of the patient from baseline, reported as 7-point ordinal scale: no change, minimal, moderate, and major worsening as well as minimal, moderate and major improvement.
Time frame: Weeks 12 and 24
Changes in Sit to Stand Test From Baseline to Week 12
Change in Sit to Stand test score from baseline to follow up. Reps are the total number of complete stands a person can execute within 30 seconds without using their arms.
Time frame: Baseline (week 0) to 12 weeks
Changes in Sit to Stand Test From Baseline to Week 24
Change in Sit to Stand test score from baseline to follow up. Reps are the total number of complete stands a person can execute within 30 seconds without using their arms.
Time frame: Baseline (week 0) to 24 weeks
Change in High-Resolution Computed Tomography (HRCT) Chest From Baseline
HRCT patterns will be analyzed using semi-quantitative and quantitative image based scoring to summarize an image as normal or abnormal. Change of summary status from baseline to follow up. Patterns include: Ground glass, Consolidation / Air Space, Mixed GGO/AS, Parenchymal Micronodules, Reticular Opacities, Linear Opacities or Septal Lines, Peribronchovascular Thickening, Honeycombing, and Traction Bronchiectasis.
Time frame: Baseline (week 0) to 24 weeks
Adverse Events (AEs) and Tolerance
All AEs and tolerance event will be compared between treatment arms * Percentage of subjects who discontinue study drug * Patients with any AEs * Patients with Serious Adverse Event (SAE)s (includes patient with AE of special interest) * Patients with AEs of special interest (gastrointestinal perforation and hepatic injury)
Time frame: Baseline (week 0) to week 24 plus 28 day follow-up
Rate of Patient Recruitment, Enrollment, Screen Failure, and Dropout Rates Between the Local Sites and the Remote Site of Physician Referred Patients.
Compare the participant recruitment, enrollment, screen failure and drop out rates between participants recruited through local clinical trial site vs. remote clinical trial site physician referrals. Not all participants were enrolled, and not all participants were physician referrals. 57 of 62 enrolled participants were physician referrals. 44 of 49 randomized participants were physician referrals.
Time frame: Patient recruitment to randomization. Median of 51 days from recruitment to randomization. Randomization occurred at baseline.
Participants were across 11 clinical sites and 1 remote site (the University of Pittsburgh only). The University of Pittsburgh also served as a clinical site and the coordinating center. Participants enrolled and randomized from the 11 clinical sites are referred to as local site patients, and patients enrolled and randomized from the University of Pittsburgh remote site are referred to as remote site patients. Remote patients were solely managed through the University of Pittsburgh.
| Milestone | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Started | 24 | 25 |
| Completed | 22 | 22 |
| Not completed | 2 | 3 |
| Milestone | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Started | 22 | 22 |
| Completed | 22 | 20 |
| Not completed | 0 | 2 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Actual Baseline | 17.1 ± 18.8 | 20.9 ± 16.0 |
| Change Baseline to 12 Weeks | 0.6 ± 10.6 | 2.1 ± 11.4 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Dyspnea Score | 0.3 ± 10.3 | 2.8 ± 16.9 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Dyspnea domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Dyspnea Score | -0.3 ± 7.6 | 0.9 ± 16.4 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Cough domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Cough Score | 8.0 ± 16.7 | -0.4 ± 12.3 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Cough domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Cough Score | -1.3 ± 17 | -2.9 ± 18.8 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Energy domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Energy Score | -0.6 ± 11.8 | -3.1 ± 12.2 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Energy domain score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Energy Score | 3.9 ± 11.1 | -2.8 ± 11.7 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Symptoms module score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Symptoms Score | 2.7 ± 9.8 | -0.5 ± 9.2 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Symptoms module score. Scoring is performed as a summary score. Summary score range from 0-100, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Symptoms Score | 1.0 ± 8.3 | -1.0 ± 12.0 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Impacts module score. Scoring is performed as a summary score. Summary score range from 0-1, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Impacts Score | -0.04 ± 0.11 | -0.04 ± 0.15 |
The Living with Pulmonary Fibrosis (L-PF) questionnaire is a 44 item questionnaire with two modules: Symptoms (23 items) and Impacts (21 items). The Symptoms module yields three domain scores: 1) dyspnea, 2) cough, and 3) energy.The Impacts module yields a single Impacts score. Impacts module score. Scoring is performed as a summary score. Summary score range from 0-1, the higher the score the greater the impairment.
| score on a scale | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Living With Pulmonary Fibrosis Impacts Score | -0.02 ± 0.13 | -0.05 ± 0.16 |
Percentage of patients requiring an increased dose or a change in their glucocorticoid (GC) / immunosuppression (IS) agent for clinical worsening/flare of MA-ILD
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Immunosuppressive (IS) Regimen | 0 | 2 |
FVC (ml) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.
| mL | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks | -30.5 ± 235.6 | 16.7 ± 199.9 |
FVC (ml) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 12 Weeks | -0.7 ± 8.9 | 0.6 ± 8.1 |
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.
| mL | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks | -37.3 ± 210.7 | 9 ± 156.8 |
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in Forced Vital Capacity (FVC) (mL) From Baseline to 24 Weeks | -0.8 ± 8.3 | 0.4 ± 8.0 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Absolute change is final value - initial value.
| % of healthy standard | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 12 | -0.7 ± 6.2 | 0.7 ± 5.1 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 12 | -0.5 ± 8.9 | 0.8 ± 8.1 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Absolute change is final value - initial value.
| % of healthy standard | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in Forced Vital Capacity FVC (%) From Baseline to Week 24 | -0.6 ± 5.7 | 0.7 ± 4.8 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in Forced Vital Capacity FVC (%) From Baseline to Week 24 | -0.4 ± 8.3 | 0.8 ± 8.0 |
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Declined ≥5% | 4 | 3 |
| Declined ≥7.5% | 4 | 2 |
| Declined ≥10% | 1 | 2 |
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Declined ≥5% | 5 | 3 |
| Declined ≥7.5% | 4 | 2 |
| Declined ≥10% | 3 | 1 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Decline ≥5% | 4 | 3 |
| Decline ≥7.5% | 4 | 2 |
| Decline ≥10% | 1 | 2 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. a decline ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Decline ≥5% | 5 | 3 |
| Decline ≥7.5% | 4 | 2 |
| Decline ≥10% | 2 | 1 |
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Stable | 11 | 11 |
| Improved ≥5% | 5 | 4 |
| Improved ≥7.5% | 4 | 3 |
| Improved ≥10% | 2 | 2 |
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Stable | 10 | 10 |
| Improved ≥5% | 7 | 7 |
| Improved ≥7.5% | 2 | 4 |
| Improved ≥10% | 1 | 1 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Stable | 11 | 11 |
| Improved ≥5% | 5 | 4 |
| Improved ≥7.5% | 4 | 4 |
| Improved ≥10% | 3 | 2 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Percent change is calculated based on change from baseline to a follow up visit. Participants may be included in multiple categories (i.e. an improvement ≥10% will be counted as ≥10%, ≥7.5%, and ≥5%).
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Stable | 10 | 10 |
| Improved ≥5% | 7 | 7 |
| Improved ≥7.5% | 3 | 5 |
| Improved ≥10% | 1 | 1 |
FVC (mL) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as mL. Time to designated change is calculated based on change from baseline to a follow up visit and time since baseline.
| Weeks | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| 5% Improvement | 17.7 ± 6.2 | 18.7 ± 6.6 |
| 7.5% Improvement | 14.8 ± 5.2 | 18.8 ± 6.7 |
| 10% Improvement | 16.3 ± 6.7 | 15.7 ± 7.1 |
| 5% Decline | 17.9 ± 6.4 | 14.9 ± 6 |
| 7.5% Decline | 17.1 ± 6.4 | 12 ± 0 |
| 10% Decline | 20.0 ± 6.9 | 12 ± 0 |
FVC (%) is forced vital capacity parameter derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Time to designated change is calculated based on change from baseline to a follow up visit and time since baseline.
| Weeks | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| 5% Improvement | 17.7 ± 6.2 | 18.7 ± 6.6 |
| 7.5% Improvement | 16.2 ± 5.8 | 18.7 ± 6.6 |
| 10% Improvement | 15.3 ± 5.8 | 15.7 ± 7.1 |
| 5% Decline | 17.9 ± 6.4 | 14.9 ± 6 |
| 7.5% Decline | 17.1 ± 6.4 | 12 ± 0 |
| 10% Decline | 18.1 ± 8.6 | 12 ± 0 |
Defined as either time for event a, b or c. Event a. ≥ 10% decline in FVC (mL) or death or transplant. Event b. ILD worsening definition (per protocol) or death or transplant. Event c. non-elective hospitalization for ILD worsening/flare or death or lung transplant.
| Weeks | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Time to Progression | 15.2 ± 9.8 | 15.8 ± 5.8 |
Validity of FVC (mL) by home spirometry is measured as intraclass correlation coefficient with FVC (mL) obtained by gold standard clinic spirometry. Unsupervised home spirometry values taken +/- 7 days from the in-clinic spirometry dates were averaged to calculate observational values.
| mL | In-Clinic Spirometry | Supervised Home Spirometry | Unsupervised Home Spirometry |
|---|---|---|---|
| FVC (mL) at baseline | 2481 ± 841 | 2489 ± 819 | 2577 ± 848 |
| FVC (mL) at Week 12 | 2507 ± 887 | 2448 ± 881 | 2493 ± 898 |
| FVC (mL) at Week 24 | 2465 ± 851 | 2535 ± 872 | 2449 ± 877 |
Reliability of FVC (mL) by home spirometry is measured as spearman correlation with FVC (mL) of test (baseline) and re-test (Week 12). Unsupervised home spirometry values taken +/- 7 days from the test and re-test dates were averaged to calculate observational values.
| mL | Supervised Home Spirometry | Unsupervised Home Spirometry |
|---|---|---|
| FVC (mL) at baseline | 2330 (1960 to 2910) | 2295 (2020 to 2925) |
| FVC (mL) at Week 12 | 2230 (1915 to 2975) | 2190 (1850 to 3020) |
DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.
| % of healthy standard | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in DLCO(%) From Baseline to 12 Weeks | 1.6 ± 20.5 | 0.3 ± 7.6 |
DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in DLCO(%) From Baseline to 12 Weeks | 5.2 ± 23.3 | 1.6 ± 18.0 |
DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.
| % of healthy standard | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in DLCO(%) From Baseline to 24 Weeks | 3.7 ± 23.1 | -2.4 ± 11.5 |
DLCO(%) is diffusing capacity of the lungs for carbon monoxide (DLCO) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in DLCO(%) From Baseline to 24 Weeks | 6.3 ± 29.6 | -2.9 ± 18.9 |
FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.
| mL | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in FEV1(mL) From Baseline to 12 Weeks | -104.0 ± 305.1 | -21.1 ± 163.1 |
FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in FEV1(mL) From Baseline to 12 Weeks | -4.2 ± 12.6 | -1.3 ± 7.8 |
FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Absolute change is final value - initial value.
| mL | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in FEV1(mL) From Baseline to 24 Weeks | -113.2 ± 229.6 | -49.5 ± 122 |
FEV1(mL) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as mL. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in FEV1(mL) From Baseline to 24 Weeks | -4.5 ± 9.8 | -2.9 ± 8.2 |
FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.
| % of healthy standard | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in FEV1(%) From Baseline to 12 Weeks | -3.4 ± 9.6 | -0.5 ± 5.0 |
FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in FEV1(%) From Baseline to 12 Weeks | -3.9 ± 12.7 | -1.0 ± 7.8 |
FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Absolute change is final value - initial value.
| % of healthy standard | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Absolute Change in FEV1(%) From Baseline to 24 Weeks | -3.2 ± 7.5 | -1.3 ± 4.7 |
FEV1(%) is forced expiratory volume over 1 second (FEV1) derived from a pulmonary function study (PFT) in volume as percentage predicted of healthy standards. Relative change is (final value / initial value)\*100.
| percent change | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Relative Change in FEV1(%) From Baseline to 24 Weeks | -4.0 ± 9.9 | -2.4 ± 8.2 |
Connective Tissue Disease (CTD)-ILD outcome as per Outcome Measures in Rheumatoid Arthritis Clinical Trials (OMERACT), which is defined as the occurrence of any of the following: death, lung transplant, FVC ≥10% decline, or FVC ≥5% decline with DLCO ≥15% decline. Clinical worsening is defined as death, lung transplant, new/worsening O2 requirement at rest (\>2L), non-elective hospitalization for ILD clinical worsening/flare, ILD worsening definition (per protocol), or out of protocol rescue medication for ILD clinical worsening/flare.
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Week 12 | 18 | 15 |
| Week 24 | 17 | 16 |
Change of steroid dosage (mg/day) from baseline to follow up.
| mg/day | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Week 12 | 0 ± 1.28 | 1.72 ± 7.93 |
| Week 24 | 4.34 ± 15.11 | 0.99 ± 7.73 |
Change in supplemental oxygen requirement (L) from baseline to follow up.
| L | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Supplemental Oxygen Needs From Baseline to Week 12 | 0 ± 0.1 | 0 ± 0.6 |
Change in supplemental oxygen requirement (L) from baseline to follow up.
| L | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Change in Supplemental Oxygen Needs From Baseline to Week 24 | 0 ± 0.1 | -0.2 ± 0.6 |
Patient Assessment of Change (also known as Patient Global Impression of Change): Overall Assessment of Change by Patient. Patient overall assessment of change in disease status from baseline, reported as 7-point ordinal scale: no change, minimal, moderate, and major worsening as well as minimal, moderate and major improvement.
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Week 12 — Major improvement | 0 | 0 |
| Week 12 — Moderate improvement | 1 | 4 |
| Week 12 — Minimal improvement | 3 | 7 |
| Week 12 — No change | 14 | 8 |
| Week 12 — Minimal worsening | 3 | 2 |
| Week 12 — Moderate worsening | 1 | 1 |
| Week 12 — Major worsening | 0 | 0 |
| Week 24 — Major improvement | 0 | 0 |
| Week 24 — Moderate improvement | 1 | 5 |
| Week 24 — Minimal improvement | 6 | 7 |
| Week 24 — No change | 8 | 7 |
| Week 24 — Minimal worsening | 6 | 1 |
| Week 24 — Moderate worsening | 0 | 0 |
| Week 24 — Major worsening | 1 | 0 |
Physician's overall assessment of change in disease status of the patient from baseline, reported as 7-point ordinal scale: no change, minimal, moderate, and major worsening as well as minimal, moderate and major improvement.
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Disease activity at Week 12 — Major improvement | 0 | 0 |
| Disease activity at Week 12 — Moderate improvement | 1 | 1 |
| Disease activity at Week 12 — Minimal improvement | 2 | 5 |
| Disease activity at Week 12 — No change | 14 | 13 |
| Disease activity at Week 12 — Minimal worsening | 3 | 3 |
| Disease activity at Week 12 — Moderate worsening | 1 | 0 |
| Disease activity at Week 12 — Major worsening | 0 | 0 |
| Disease activity at Week 24 — Major improvement | 0 | 0 |
| Disease activity at Week 24 — Moderate improvement | 0 | 1 |
| Disease activity at Week 24 — Minimal improvement | 4 | 5 |
| Disease activity at Week 24 — No change | 13 | 12 |
| Disease activity at Week 24 — Minimal worsening | 4 | 1 |
| Disease activity at Week 24 — Moderate worsening | 0 | 0 |
| Disease activity at Week 24 — Major worsening | 1 | 0 |
| Disease damage at Week 12 — Major improvement | 0 | 0 |
| Disease damage at Week 12 — Moderate improvement | 0 | 0 |
| Disease damage at Week 12 — Minimal improvement | 1 | 0 |
| Disease damage at Week 12 — No change | 19 | 21 |
| Disease damage at Week 12 — Minimal worsening | 1 | 1 |
| Disease damage at Week 12 — Moderate worsening | 0 | 0 |
| Disease damage at Week 12 — Major worsening | 0 | 0 |
| Disease damage at week 24 — Major improvement | 0 | 0 |
| Disease damage at week 24 — Moderate improvement | 0 | 0 |
| Disease damage at week 24 — Minimal improvement | 0 | 2 |
| Disease damage at week 24 — No change | 21 | 16 |
| Disease damage at week 24 — Minimal worsening | 1 | 1 |
| Disease damage at week 24 — Moderate worsening | 0 | 0 |
| Disease damage at week 24 — Major worsening | 0 | 0 |
Change in Sit to Stand test score from baseline to follow up. Reps are the total number of complete stands a person can execute within 30 seconds without using their arms.
| Reps | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Changes in Sit to Stand Test From Baseline to Week 12 | 0.1 ± 1.4 | 0.4 ± 3.7 |
Change in Sit to Stand test score from baseline to follow up. Reps are the total number of complete stands a person can execute within 30 seconds without using their arms.
| Reps | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Changes in Sit to Stand Test From Baseline to Week 24 | 0.3 ± 1.9 | 1.4 ± 2.7 |
HRCT patterns will be analyzed using semi-quantitative and quantitative image based scoring to summarize an image as normal or abnormal. Change of summary status from baseline to follow up. Patterns include: Ground glass, Consolidation / Air Space, Mixed GGO/AS, Parenchymal Micronodules, Reticular Opacities, Linear Opacities or Septal Lines, Peribronchovascular Thickening, Honeycombing, and Traction Bronchiectasis.
| Participants | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care |
|---|---|---|
| Ground glass — Normal to normal | 0 | 0 |
| Ground glass — Normal to abnormal | 1 | 0 |
| Ground glass — Abnormal to normal | 0 | 0 |
| Ground glass — Abnormal to abnormal | 21 | 18 |
| Consolidation / Air Space — Normal to normal | 15 | 11 |
| Consolidation / Air Space — Normal to abnormal | 4 | 0 |
| Consolidation / Air Space — Abnormal to normal | 1 | 2 |
| Consolidation / Air Space — Abnormal to abnormal | 2 | 5 |
| Mixed GGO/AS — Normal to normal | 19 | 12 |
| Mixed GGO/AS — Normal to abnormal | 1 | 0 |
| Mixed GGO/AS — Abnormal to normal | 0 | 2 |
| Mixed GGO/AS — Abnormal to abnormal | 2 | 4 |
| Parenchymal Micronodules — Normal to normal | 20 | 13 |
| Parenchymal Micronodules — Normal to abnormal | 1 | 1 |
| Parenchymal Micronodules — Abnormal to normal | 0 | 1 |
| Parenchymal Micronodules — Abnormal to abnormal | 1 | 3 |
| Reticular Opacities — Normal to normal | 1 | 1 |
| Reticular Opacities — Normal to abnormal | 1 | 1 |
| Reticular Opacities — Abnormal to normal | 1 | 0 |
| Reticular Opacities — Abnormal to abnormal | 19 | 16 |
| Linear Opacities or Septal Lines — Normal to normal | 0 | 1 |
| Linear Opacities or Septal Lines — Normal to abnormal | 1 | 0 |
| Linear Opacities or Septal Lines — Abnormal to normal | 0 | 0 |
| Linear Opacities or Septal Lines — Abnormal to abnormal | 21 | 17 |
| Peribronchovascular Thickening — Normal to normal | 12 | 9 |
| Peribronchovascular Thickening — Normal to abnormal | 2 | 2 |
| Peribronchovascular Thickening — Abnormal to normal | 4 | 4 |
| Peribronchovascular Thickening — Abnormal to abnormal | 4 | 3 |
| Honeycombing — Normal to normal | 16 | 10 |
| Honeycombing — Normal to abnormal | 0 | 1 |
| Honeycombing — Abnormal to normal | 0 | 0 |
| Honeycombing — Abnormal to abnormal | 6 | 7 |
| Traction Bronchiectasis — Normal to normal | 0 | 1 |
| Traction Bronchiectasis — Normal to abnormal | 1 | 0 |
| Traction Bronchiectasis — Abnormal to normal | 0 | 0 |
| Traction Bronchiectasis — Abnormal to abnormal | 21 | 17 |
All AEs and tolerance event will be compared between treatment arms * Percentage of subjects who discontinue study drug * Patients with any AEs * Patients with Serious Adverse Event (SAE)s (includes patient with AE of special interest) * Patients with AEs of special interest (gastrointestinal perforation and hepatic injury)
| Participants | Experimental Phase: Placebo Plus Standard of Care | Experimental Phase: Nintedanib Plus Standard of Care | Open Label Phase: Nintedanib Plus Standard of Care |
|---|---|---|---|
| Discontinued study drug | 4 | 6 | 8 |
| Any Adverse Event | 16 | 21 | 36 |
| Serious Adverse Event | 0 | 6 | 5 |
| Adverse Event of special interest | 0 | 1 | 0 |
Compare the participant recruitment, enrollment, screen failure and drop out rates between participants recruited through local clinical trial site vs. remote clinical trial site physician referrals. Not all participants were enrolled, and not all participants were physician referrals. 57 of 62 enrolled participants were physician referrals. 44 of 49 randomized participants were physician referrals.
| Participants | Local Physician Referred | Remote Physician Referred |
|---|---|---|
| Pre-screened | 24 | 76 |
| Screened (enrolled) | 20 | 37 |
| Randomized | 16 | 28 |
Collected over Baseline (Week 0) to end of study (Week 24) plus 28 day follow-up. 28 week observation period total.. Non-serious events are listed at a 4% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Experimental Phase: Nintedanib Plus Standard of Care | 0/25 (0%) | 6/25 (24%) | 21/25 (84%) |
| Experimental Phase: Placebo Plus Standard of Care | 0/24 (0%) | 0/24 (0%) | 16/24 (66.7%) |
| Open Label Phase: Nintedanib Plus Standard of Care | 0/44 (0%) | 5/44 (11.4%) | 36/44 (81.8%) |
| Event | Experimental Phase: Nintedanib Plus Standard of Care | Experimental Phase: Placebo Plus Standard of Care | Open Label Phase: Nintedanib Plus Standard of Care |
|---|---|---|---|
| Hepatic enzyme increasedHepatobiliary disorders | 1/25 | 0/24 | 0/44 |
| HysterectomyReproductive system and breast disorders | 1/25 | 0/24 | 0/44 |
| MigraineNervous system disorders | 1/25 | 0/24 | 0/44 |
| Mild heart attackCardiac disorders | 1/25 | 0/24 | 0/44 |
| Renal calculiRenal and urinary disorders | 1/25 | 0/24 | 0/44 |
| Right renal artery stenosisRenal and urinary disorders | 1/25 | 0/24 | 0/44 |
| Soft tissue infectionInfections and infestations | 1/25 | 0/24 | 0/44 |
| Brain AneurysmVascular disorders | 0/25 | 0/24 | 1/44 |
| Eye infectionInfections and infestations | 0/25 | 0/24 | 1/44 |
| PancytopeniaBlood and lymphatic system disorders | 0/25 | 0/24 | 1/44 |
| Event | Experimental Phase: Nintedanib Plus Standard of Care | Experimental Phase: Placebo Plus Standard of Care | Open Label Phase: Nintedanib Plus Standard of Care |
|---|---|---|---|
| DiarrheaGastrointestinal disorders | 12/25 | 5/24 | 8/44 |
| DyspneaRespiratory, thoracic and mediastinal disorders | 1/25 | 4/24 | 1/44 |
| NauseaGastrointestinal disorders | 3/25 | 2/24 | 2/44 |
| Weight lossMetabolism and nutrition disorders | 3/25 | 0/24 | 2/44 |
| VomitingGastrointestinal disorders | 1/25 | 2/24 | 1/44 |
| CoughRespiratory, thoracic and mediastinal disorders | 1/25 | 2/24 | 2/44 |
| Upper respiratory InfectionInfections and infestations | 1/25 | 1/24 | 3/44 |
| DyspepsiaGastrointestinal disorders | 0/25 | 0/24 | 2/44 |
| Gastrointestinal PainGastrointestinal disorders | 1/25 | 0/24 | 2/44 |
| FatigueGeneral disorders | 0/25 | 0/24 | 2/44 |
| Age, Categorical(Participants) | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 17 | 13 | 30 |
| >=65 years | 7 | 12 | 19 |
| Age, Continuous(years) | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care | Total |
|---|---|---|---|
| Median | 57 (48.5 to 66) | 62 (50 to 68) | 58 (49 to 67) |
| Sex: Female, Male(Participants) | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care | Total |
|---|---|---|---|
| Female | 18 | 15 | 33 |
| Male | 6 | 10 | 16 |
| Ethnicity (NIH/OMB)(Participants) | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care | Total |
|---|---|---|---|
| Hispanic or Latino | 0 | 4 | 4 |
| Not Hispanic or Latino | 24 | 21 | 45 |
| Unknown or Not Reported | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 1 | 3 | 4 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 2 | 7 | 9 |
| White | 21 | 13 | 34 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 2 | 2 |
| Region of Enrollment(participants) | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care | Total |
|---|---|---|---|
| United States | 24 | 25 | 49 |
| BMI, Continuous(kilograms / meters squared) | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care | Total |
|---|---|---|---|
| Median | 29.6 (27 to 33.8) | 28.5 (23.4 to 37.5) | 29.1 (25.5 to 34.9) |
| Predicted FVC%, Continuous(percent) | Placebo Plus Standard of Care, Then Nintedanib Plus Standard of Care | Nintedanib Plus Standard of Care | Total |
|---|---|---|---|
| Median | 67.7 (62.3 to 75.7) | 58.2 (54.4 to 71.2) | 64.4 (57.9 to 74) |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Sharing of individual participant data will require written approval from sponsor and steering committee.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Time frame: Data requests will not be accepted prior to final publication of the trial.
Access criteria: All data requests will require written approval from sponsor and steering committee prior to release of data
Ran from Aug 2023 to primary completion in Mar 2025, 19 months.
Results were first posted in Oct 2026, 1 year 6 months after primary completion. A results delay was requested in Feb 2026.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Nintedanib
Rohit Aggarwal, MD